KAYA TİLKİ, E. And Ozturk, S. E. 2024. The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*. ISTANBUL JOURNAL OF PHARMACY , no.2 , 215-222.

KAYA TİLKİ, E., & Ozturk, S. E., (2024). The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*. ISTANBUL JOURNAL OF PHARMACY , no.2, 215-222.

KAYA TİLKİ, ELİF, And Selin Engur Ozturk. "The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*," ISTANBUL JOURNAL OF PHARMACY , no.2, 215-222, 2024

KAYA TİLKİ, ELİF K. And Ozturk, Selin E. . "The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*." ISTANBUL JOURNAL OF PHARMACY , no.2, pp.215-222, 2024

KAYA TİLKİ, E. And Ozturk, S. E. (2024) . "The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*." ISTANBUL JOURNAL OF PHARMACY , no.2, pp.215-222.

@article{article, author={ELİF KAYA TİLKİ And author={Selin Engur Ozturk}, title={The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*}, journal={ISTANBUL JOURNAL OF PHARMACY}, year=2024, pages={215-222} }